Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.

Oncotarget - 19 Jan 2016

Umelo Ijeoma, Noeparast Amir, Chen Gang, Renard Marleen, Geers Caroline, Vansteenkiste Johan, Giron Philippe, De Wever Olivier, Teugels Erik, De Grève Jacques

Abstract excerpt

Somatic mutations found within the tyrosine kinase domain (TKD) of the human epidermal growth factor (HER) family of receptors have been implicated in the development and progression of non-small cell lung cancer (NSCLC). However, no conclusive reports have described pathogenic mutations in kinase-impaired HER3. Here, we report a case of an advanced chemotherapy-resistant NSCLC, harboring a novel HER3(V855A)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Neuregulin-1

Share to Protein Kinase Inhibitors

Share to Receptor, ErbB-2

Share to Receptor, ErbB-3

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 26689995
DOI: 10.18632/oncotarget.6585
PMCID: PMC4823091

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.PMID 26689995Read ↗

Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives.Semantic proximity Read ↗

Molecular Pathways: HER3 Targeted TherapySemantic proximity Read ↗

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer TherapySemantic proximity Read ↗

Activating HER3 mutations in breast cancerSemantic proximity Read ↗

Advances in Targeting HER3 as an Anticancer TherapySemantic proximity Read ↗

HER3/ErbB3, an emerging cancer therapeutic target.Semantic proximity Read ↗

The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study.Semantic proximity Read ↗

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.Semantic proximity Read ↗

HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of CancerSemantic proximity Read ↗

Epidermal growth factor receptor as a target enzyme in cancer therapy: Structural and functional insights from crystallography.Semantic proximity Read ↗

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.Semantic proximity Read ↗

Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.